Marie Hauguel-Moreau, Paul Guedeney, Claire Dauphin, Vincent Auffret, Eloi Marijon, Philippe Aldebert, Jean-Michel Clerc, Farzin Beygui, Meyer Elbaz, Wissam Abi Khalil, Antoine Da Costa, Jean-Christophe Macia, Simon Elhadad, Guillaume Cayla, Delphine Brugier, Johanne Silvain, Nadjib Hammoudi, Guillaume Duthoit, Eric Vicaut, Gilles Montalescot
INTRODUCTION: Atrial arrhythmia is the most common complication of patent foramen ovale (PFO) closure. The real incidence of post-PFO closure atrial arrhytmia and whether this complication can be prevented is unknown. METHODS/DESIGN: The Assessment of Flecainide to Lower the patent foramen Ovale closure risk of Atrial fibrillation or Tachycardia (AFLOAT) trial is a prospective, national, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the endpoints (PROBE design)...
January 12, 2024: European Heart Journal. Cardiovascular Pharmacotherapy